A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA

Overview

Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets. Informed, Motivated, Aware and Responsible Adolescents and Adults- South Africa (IMARA-SA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. This pilot study will assess feasibility in preparation for a randomized controlled trial (RCT). Additionally, the pilot will examine the preliminary effectiveness of IMARA-SA in reducing sexually transmitted infections (STI) and increasing uptake of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at follow-up among AGYW. About 60 AGYW-FC dyads will be enrolled and randomized to IMARA-SA or a health-promotion control arm. Following randomization, the dyads will participate in an ~2-day group workshop (~10 hours), which includes joint and separate mother and daughter activities. AGYW and FC will complete baseline assessments and follow-up assessments approximately 6 months later. Assessments will include surveys, STIs testing (for chlamydia and gonorrhea), and uptake of HTC and a 1-month PrEP prescription. Additionally, the intervention's implementation (e.g., acceptability) will be explored.

Full Title of Study: “Multilevel Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: May 15, 2021

Interventions

  • Behavioral: IMARA-SA (intervention group)
    • The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women’s sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA’s goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
  • Behavioral: Health promotion control group
    • The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.

Arms, Groups and Cohorts

  • Experimental: IMARA-SA intervention arm
    • Participants randomized to the IMARA-SA arm will receive the IMARA-SA intervention (i.e., the intervention group).
  • Experimental: Health promotion control arm
    • Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of adolescent girls and young women (AGYW) with a sexually transmitted infection (STI) at baseline and follow-up
    • Time Frame: ~6 months (from baseline to follow-up)
    • A positive test for at least one of two STIs: chlamydia and/or gonorrhea
  • Proportion of AGYW who complete HIV testing and counseling (HTC) at baseline and follow-up
    • Time Frame: ~6 months (from baseline to follow-up)
    • Completion of HTC
  • Proportion of AGYW who elect to take pre-exposure prophylaxis (PrEP) at baseline and follow-up
    • Time Frame: ~6 months (from baseline to follow-up)
    • Uptake of PrEP

Secondary Measures

  • Proportion of AGYW who report risky sexual behavior at baseline and follow-up
    • Time Frame: ~6 months (from baseline to follow-up)
    • Sexual behavior (e.g., condom use, substance use during sex, number of partners, concurrent partners) will be measured via self-report using the AIDS Risk Behavior Assessment (ARBA) (Donenberg, 2001)
  • Proportion of AGYW who report adherence to PrEP at baseline and follow-up
    • Time Frame: ~6 months (from baseline to follow-up)
    • Adherence to PrEP (where appropriate) will be measured via self-report using items from the Wilson scale (2017)

Participating in This Clinical Trial

Inclusion criteria for AGYW include: 1. Black or mixed race; 2. 15-19 years-old; 3. residing in Klipfontein/Mitchells Plain (K/MP); 4. speak isiXhosa or English or a combination of these languages. Inclusion criteria for FC include: 1. identified by AGYW as a FC; 2. 24 years and older; 3. living with or in daily contact with the AGYW; 4. speak isiXhosa or English or a combination of these languages. Exclusion Criteria:

AGYW will be excluded from the study if they do not have a FC to participate in the study. AGYW and FC will be excluded from the study if they: 1. are unable to understand the consent/assent process and provide written informed consent; 2. are currently enrolled in another research study addressing HIV/STIs/PrEP; 3. participated in the IMARA-SA adaptation process. AGYW and FC must agree to participate as a dyad. AGYW refusal will supersede FC consent.

Gender Eligibility: Female

Participants will be eligible to participate if they are female.

Minimum Age: 15 Years

Maximum Age: 19 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Illinois at Chicago
  • Collaborator
    • Desmond Tutu HIV Centre
  • Provider of Information About this Clinical Study
    • Principal Investigator: Geri Donenberg, Professor and Director, Center for Dissemination and Implementation Science – University of Illinois at Chicago
  • Overall Official(s)
    • Geri R Donenberg, PhD, Principal Investigator, University of Illinois Chicago
    • Linda-Gail Bekker, MBChB, PhD, Principal Investigator, Desmond Tutu HIV Centre

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.